PrEP
-
News
Teso set to get 100 doses of Lenacapavir, a new long-acting HIV prevention drug
SOROTI CITY, April, 20, 2026 — As part of its ongoing commitment to strengthening HIV prevention and care, the AIDS Information Centre [AIC] has conducted a targeted training for health workers in…
Read More » -
News
Uganda rolls out HIV prevention jab in 100 health facilities
KAMPALA, April 17, 2026 — Uganda has commenced the rollout of Lenacapavir, a long-acting injectable drug administered every six months to prevent HIV infection among people at substantial risk. The rollout, which…
Read More » -
News
Gov’t approves use of HIV injectables in Uganda
KAMPALA, January 5, 2025 — The National Drug Authority [NDA] has approved the use of lenacapavir, a twice-yearly HIV prevention [PrEP] injection manufactured by Gilead Sciences, a U.S.-based company. The approval is…
Read More »